1. Reply to 'Tolerogenic insulin peptide therapy precipitates type 1 diabetes'
- Author
-
Daniel, Carolin, Weigmann, Benno, and von Boehmer, Harald
- Subjects
Reply ,0301 basic medicine ,Agonist ,Regulatory T cell ,medicine.drug_class ,medicine.medical_treatment ,Immunology ,Peptide ,T-Lymphocytes, Regulatory ,Epitopes ,03 medical and health sciences ,0302 clinical medicine ,Mice, Inbred NOD ,Immune Tolerance ,medicine ,Animals ,Humans ,Insulin ,Immunology and Allergy ,Everolimus ,chemistry.chemical_classification ,Type 1 diabetes ,business.industry ,TOR Serine-Threonine Kinases ,Vaccination ,FOXP3 ,Forkhead Transcription Factors ,medicine.disease ,Gastrointestinal Microbiome ,Diabetes Mellitus, Type 1 ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,Female ,business ,Immunosuppressive Agents ,030217 neurology & neurosurgery - Abstract
In this issue of JEM, Bergman et al. challenge the data published in a previous JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Daniel et al. provide a response to these data., In this issue of JEM, Bergman et al. (https://doi.org/10.1084/jem.20160471) challenge the data published in our previous JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Here, we provide a response to these data and suggest that appropriate subimmunogenic conditions are required to induce Foxp3+ regulatory T cell conversion.
- Published
- 2017
- Full Text
- View/download PDF